Please wait a minute...
Office
期刊信息
  • 临床肿瘤学杂志
    主管:解放军无锡联勤保障中心
    主办:解放军东部战区总医院
    编辑出版:临床肿瘤学杂志编辑部
    主编:秦叔逵
    编辑部主任:龚新雷
    地址:南京市杨公井34标34号
    邮编:210002
    电话:(025)84400143;80864363
    E-mail: lczlx@vip.163.com
    邮发代号:28-267
    刊期:月刊
    定价:每期15元,全年180元
    标准刊号: ISSN 1009-0460
    CN 32-1577/R
     
Table of Content
31 May 2014, Volume 19 Issue 5
专家论坛
Research progress of new oral multikinase inhibitor regorafenib in the treatment of cancer
LI Jin
Chinese Clinical Oncology. 2014, 19 (5):  385. 
Abstract ( 1065 )   PDF(pc) (1136KB) ( 1098 )   Save
Targeted therapies by means of compounds that inhibit a specific target molecule represent a new perspective in the treatment of cancer. Various signaling pathways have been implicated in the development and progression of cancer. There is a general agreement that molecules interfering simultaneously with multiple targets might be more effective than single target agents. Regorafenib (BAY 73-4506) is a novel, oral multikinase inhibitor, which demonstrates a broad spectrum of antitumor activity, probably due to the targeting of several angiogenic, oncogenic and stromal kinases. On September 2012, regorafenib was approved by US Food and Drug Administration(FDA) for previously heavy treated metastatic colorectal cancer. On February 2013, US FDA expanded the approved use to treat patients with advanced gastrointestinal stromal tumors. Two large, randomized,international multicentre,phase Ⅲ clinical trial in patients with metastatic colorectal cancer and gastrointestinal stromal tumour treated by regorafenib were finished. The CORRECT trial evaluated regorafenib for the treatment of patients with metastatic colorectal cancer who had progressed after standard therapies. The results confirmed that regorafenib was associated with significant improvements in overall survival. The GRID trial showed that regorafenib could provide a significant improvement in progressionfree survival compared with placebo in patients with metastatic gastrointestinal stromal tumour following failure of imatinib and sunitinib. The toxicity profile of regorafenib is comparable with other oral multikinase inhibitors with similar molecular targets. Most toxicities associated with regorafenib are mild/moderate and clinically managable. Further extensive clinical development as a single agent or in combination with standard chemotherapeutic agents in various malignant tumors is ongoing.
Related Articles | Metrics
论著
The effect of RNA interference of heparanase gene at trancription levels on capacities of invasion in hepatocellular carcinoma cell line
ZHANG Caihong, XIAO Wenhua, DONG Weiwei, ZHAO Huixia, DUAN Xinyu, LI Qiuwen, HAO Yixing, WANG Ruliang, ZHU Jianhua, YE Ming.
Chinese Clinical Oncology. 2014, 19 (5):  391. 
Abstract ( 988 )   PDF(pc) (1506KB) ( 358 )   Save

Objective To study the effects of transcription gene sciencing(TGS) and posttranscriptional gene silencing(PTGS) on interfernce of heparanase(HPA) gene in hepatocellular carcinoma cell line SMMC-7721 and its invasion ability. Methods The small interfering(siRNA) of TGS and PTGS covered promoter region and coding region of HPA gene were designed and syntheses, and then transfected into hepatocellular carcinoma cell line SMMC-7721 by neuclear trancfection. HPA expression in both mRNA and protein level were detected by RT-PCR and Western blotting at 48, 72 and 96h, and blank group was set as control. Transwell chamber experiment was used to detect the ability of invasion and migration of hepatocellular carcinoma cell line SMMC-7721 after TGS and PTGS siRNA transfected. Results Both of TGS and PTGS technique could silence HPA gene at mRNA and protein level 48 hours later after siRNA transfection. The expression of HPA gene in PTGS group was recovered 72 hours later after siRNA transfection, but HPA still kept silencing in TGS group. However, the expression of HPA gene in both of TGS and PTGS groups were recovered 96 hours later after gene transfection. The transwell chamber experiment confirmed that TGS and PTGS of HPA gene could reduce the abilities of invasion of SMCC-7721 cell, especially in TGS group. Conclusion TGS can silence HPA gene better compared with PTGS,and significantly decrease the abilities of invasion of hepatocellular carcinoma cell line SMMC-7721.

Related Articles | Metrics
The inhibitory effect of parthenolide combined with adriamycin on proliferation of leukemia Jurkat cells
WANG Xiaotao, LIU Ling, TANG Ailin, HE Yuchan.
Chinese Clinical Oncology. 2014, 19 (5):  396. 
Abstract ( 1130 )   PDF(pc) (1731KB) ( 378 )   Save
Objective To investigate the inhibitory effect of parthenolide(PTL) combined with adriamycin (ADM)on proliferation and apoptosis of adult acute T lymphoblastic leukemia Jurkat cells and their possible mechanism. Methods MTT assay was applied to calculate the half inhibitory concentration(IC50) of PTL and ADM for 48h, and detect the inhibition rates by treating Jurkat cells with different concentration groups of PTL(4,8,16μmol/L) or ADM (0.25,0.5,1μmol/L) for 48h. Flow cytometry was applied to detect the apoptosis rate by treating Jurkat cells with ADM (0.25, 0.5, 1μmol/L), PTL (4, 8, 16μmol/L), and PTL (8μmol/L) combined with ADM (0.5μmol/L) for 48h. Immunohistochemical method was employed to detect the expression of protein nuclear factor-κBp65 (NF-κBp65) treated by ADM (0.5μmol/L), PTL (8μmol/L), and PTL (8μmol/L) combined with ADM (0.5μmol/L). Blank control group was set for above experiments. Results MTT assay showed that PTL and ADM inhibited the growth of Jurkat cells in a dose-dependent manner, with IC50 of 8.11μmol/L and 0.53μmol/L at 48h. Compared with single drug groups and control group, PLT combined with ADM could significantly inhibit the proliferation of Jurkat cells. Flow cytometry showed that the apoptosis rate of Jurkat cells in PTL or ADM single agent group was in a dosedependent manner. The apoptosis rate of combined group was (84.50±5.64) %, higher than those of single agent groups and control group (P<0.05). Immunohistochemical detection showed that the positive score of NFκBp65 in PTL and PTL combined with ADM was lower than control group (P<0.05), while in ADM group was higher than control group (P<0.05), and the combined group was lower than the two single agent groups (P<0.05). Conclusion PTL may inhibit the expression of NF-κBp65 protein, raise the ability of inhibition of ADM on Jurkat cells proliferation, and promote cells apoptosis.
Related Articles | Metrics
Identify genetic predictive factors for neoadjuvant chemotherapy in patients with luminal B type locally advanced breast cancer
WANG Mei, WANG Haixin, HU Wei, XIONG Anwen, WU Meihong, LI Yongmei, WANG Wei, WANG Yajie.
Chinese Clinical Oncology. 2014, 19 (5):  401. 
Abstract ( 1056 )   PDF(pc) (2753KB) ( 481 )   Save
Objective To screen prognostic genes for neoadjuvant chemotherapy in patients with locally advanced breast cancer of luminal B type.Methods Ten locally advanced breast cancer patients of luminal B type were underwent DA regimen as neoadjuvant chemotherapy(docetaxel 75mg/m2iv, d1;epirubicin 80 mg/m2 iv, d1, 3 weeks as a cycle for 4 cycles). Based on RECIST11 standard, 10 patients were divided into pathological complete remission(pCR) group(n=3) and non-pathological complete remission(npCR) group (n=7). GeneChip human genome was used to screen prognostic genes for neoadjuvant chemotherapy in 10 luminal B breast cancer patients. Florescence quantitative PCR was conducted to confirm the different gene expression. Results Compared with npCR patients, 231 genes expression were up-regulated, 195 genes expression were downregulated in tumor samples of pCR patients;Compared with peri-tumor tissues, 357 genes expression were up-regulated and 544 genes expression were down-regulated in tumor samples of pCR patients. Compared with peri-tumor tissues, 143 genes expression were upregulated and 101 genes expression were down-regulated in the tumor samples of npCR patients. Compared with npCR patients, 98 genes expression were up-regulated and 67 genes expression were downregulated in peri-tumor samples of pCR patients. Statistically significant differences in gene expressions were noted in pCR group vs. npCR group, including 3 up-regulated genes of CYP4Z1, FGFL6 and BCAR4, as well as 3 down-regulated genes of FABP4, S100B and ALPH1L1. The expression of CYP4Z1 and BCAR4 in pCR patients was significantly lower than that of npCR patients(P<0.05) confirmed by florescence quantitative PCR. Conclusion In patients with luminal B locally advanced breast cancer, lower expression of CYP4Z1 and BCAR4 may be associated with higher pCR rates in neoadjuvant chemotherapy receiving DA regimen.
Related Articles | Metrics
A high-sensitivity detection method for plasma EGFR exon 19 deletion
XIE Li, YIN Zhenyu, WEI Jia, YU Lixia, QIAN Xiaoping, LIU Baorui.
Chinese Clinical Oncology. 2014, 19 (5):  407. 
Abstract ( 976 )   PDF(pc) (1100KB) ( 364 )   Save
Objective To establish a stable, highsensitive detection technology of EGFR19 exon deletion mutation through combined restriction fragment length polymorphism(RFLP) and fragment analysis techniques. Methods Wide type DNA was digested to reduce the background. Fragment analysis was used to assess the length of DNA. The wild-type DNA was used to dilute mutant DNA to test the sensitivity of the method. Using this method, we detected the status of EGFR 19 exon in 42 non-small cell lung cancer(NSCLC) peripheral blood plasma.Results The mutant DNA diluted in wide-type DNA was used to test the sensitivity of the method and the highest sensitivity was 1∶1000(Mt∶Wt). For the 42 plasma samples of NSCLC, 5 samples contained EGFR19 exon deletion mutation, with four cases 15bp deletion, 1 cases 24bp deletion.Conclusion We established a restriction enzyme digestion and fragment analysis based high sensitive method to detect plasma EGFR exon 19 deletion. The method can effectively identify EGFR19 exon deletion mutations in the peripheral blood.
Related Articles | Metrics
Expression of CD133,SPARC and ARID1A in gastric cancer and its clinical significance
LI Caiyan,GU Kangsheng.
Chinese Clinical Oncology. 2014, 19 (5):  411. 
Abstract ( 934 )   PDF(pc) (1535KB) ( 475 )   Save
Objective To analyze the expression of CD133, secreted protein acidic and rich in cysteine(SPARC), and AT rich interactive domain1A(ARID1A) in gastric cancer and their relationship with clinicopathological features and the prognosis of gastric cancer. Methods Expression of CD133, SPARC and ARID1A proteins were detected by immunohistochemistry (IHC), and its correlation with clinicopathologic features and survival of gastric cancer was analyzed. Results The positive rates of CD133, SPARC and ARID1A was 26.7%(24/90), 72.2%(65/90)and 30.0% (27/90) in gastric cancer. The expression of CD133, SPARC and ARID1A was not related to sex, age and tumor size, but all related to TNM stage(P<0.05). The expression of ARID1A was also related to the depths of tumor invasion and tumor differentiation(P<0.05); the expression of CD133 was related to tumor differentiation, vascular invasion, lymph node metastasis and tumor position(P<0.05);the expression of SPARC was related to lymph node metastasis and vascular invasion(P<0.05). Cox analysis showed that TNM stage, chemotherapy after surgery, and the expression of ARID1A and SPARC were independent prognostic factors influencing disease free survival (DFS); TNM stage, chemotherapy after surgery and the expression of CD133 were independent prognosis factors for overall survival (OS). The median DFS and OS were 12 months and 17 months with positive expression of CD133, while in positive expression they were 41 months and 55 months with significance (P<0.05). The median DFS and OS with high SPARC expression levels was 41 and 54 months, higher than 10 months and 25 months in low expression (P<0.05). The median DFS and OS with positive ARID1A expression were not achieved, but higher than 20 months and 37months (P<0.05). Conclusion Detecting the expression of CD133, SPARC, and ARID1A contributes to the prediction of the prognosis of gastric cancer and selection of adjuvant chemotherapy for priority patients, and provides evidence for the therapy of gastric cancer.
Related Articles | Metrics
Expression of Prdx1 in gastric cancer and its clinical significance
XU Dongyun, HE Xiaojing, WANG Jiejun, FANG Wenzheng, QIAN Jianxin, WANG Zhan, YU Guanzhen.
Chinese Clinical Oncology. 2014, 19 (5):  417. 
Abstract ( 1001 )   PDF(pc) (1589KB) ( 384 )   Save
Objective To explore the expression of peroxiredoxin 1(Prdx1) protein in gastric cancer and determine the relationship of its expression with clinical features and prognosis. Methods Tissue microarray blocks containing gastric cancer tissues and adjacent non-cancerous tissues from 120 patients were constructed. Expression of Prdx1 in gastric cancer tissues and adjacent non-cancerous tissues were analyzed using immunohistochemical study. The relationship between the expression of Prdx1 and clinicopathological characteristics were analyzed as well as the overall survival(OS).
Results The positive rates of Prdx1 in tumor and adjacent noncancerous tissues were 58.3%(70/120) and 25.0%(30/120) with significant difference(P=0.001). Overexpression of Prdx1 was significantly associated with lymph node metastasis(P=0.015)and TNM stage(P=0.006), but not with age, gender, tumor position, tumor size, differentiation and invasive depth. The median OS of patients with Prdx1 positive expression was 56.0 months, significantly shorter than 81.7months of Prdx1 negative expression(P=0.004). Multivariate analysis revealed that Prdx1 was an independent prognostic factor in patients of stage Ⅰ/Ⅱ. Conclusion Prdx1 expression significantly increases in gastric cancer, suggesting the potential role of Prdx1 in cancer development and progression. Prdx1 expression can be used to predict patients' outcome of gastric cancer.
Related Articles | Metrics
Effects of different preparing methods for gynecological cancer cells on analysis results by AFM
GAO Hongfei, HAN Yimin.
Chinese Clinical Oncology. 2014, 19 (5):  421. 
Abstract ( 971 )   PDF(pc) (2818KB) ( 582 )   Save
Objective To explore effects of different sample preparing methods including cell culture method, cell printing slice method and liquid based cytology detection technology on the morphologies of ovarian cancer and cervical cancer cells by atomic force microscope(AFM). Methods Low metastatic ovarian cancer cell line HO-8910 and highly metastatic ovarian cancer cell line HO-8910PM were cultured by cell culture method. The cell printing slice method was used to prepare the serous ovarian cancer sample. The liquid based cytology detection technology was employed to prepare squamous cell carcinoma and normal cervical cells samples. The morphologies of cells prepared by the three methods were obtained by AFM and analyzed.
Results For cancer cell samples prepared by the three methods, they all showed that the nucleus and cytoplasm increased in the dispersion morphology. Multiple nuclei easily gathered together, and superposition of coincidence caused further increase in size of cells. Main differences of three methods were as follows. For the ovarian cancer cell sample prepared by the cell culturing method, the cells were rectangular shaped, the whole length of the cells was 30-40μm, and the nucleus could not be distinguished clearly. For the ovarian cancer cell sample prepared by the cell printing slice method, the cells were in shape of irregular polygon with a round nucleus and an average diameter was about 15μm. For the squamous cell carcinoma samples prepared by the liquid based cytology detection technology, the samples presented the properties of bare cell nucleus, round nuclei was isolated with the surrounding tissue, and the average diameter was about 30μm. Conclusion Cell culture method, cell printing slice method and liquid based cytology detection technology are completely applicable for gynecological cancer cells observed by AFM tests. Different gynecological cancer cells show different morphologies on the substrate due to the effects of preparation methods.
Related Articles | Metrics
Analysis of prognostic factors in 92 patients with Siewert Ⅱ and Ⅲ type of cardia cancer
ZHANG Yue'an,LI Xiaoping,LIU Yisheng, ZHU Zhengkui, CHEN Youjun, WU Qichen, CHEN Wu,BAO Fang.
Chinese Clinical Oncology. 2014, 19 (5):  426. 
Abstract ( 973 )   PDF(pc) (1098KB) ( 341 )   Save
Objective To explore the prognostic factors in 92 patients with Siewert Ⅱ and Ⅲ type of cardia cancer.Methods Ninety-two patients with Siewert Ⅱ and Ⅲ type of cardia cancer admitted by our hospital from April 2000 to April 2012 were enrolled. The clinical data were collected and the patients were followed up for the 5-year survival rate and median overall survival(OS). The univariate analysis and Cox regression hazard model analysis were used to analyze the factors affecting the prognosis for Siewert Ⅱ and Ⅲ type of cardia cancer.Results At the end of the follow-up period(September 1, 2012), 53 out of 92 patients died with the 5-year survival rate of 27.4% and the median OS of 36.0 months. There were significant differences on 5year survival rates between different Siewert type, T stage, N stage and UICC staging(P<0.05). The 5.year survival rates were unrelated to age, histopathology, Lauren type, lymph node dissection and surgical approach. T stage and N stage were independent factors affecting the prognosis for Siewert Ⅱ, Ⅲ type of cardia cancer. Conclusion T stage and N stage were the independent factors affecting the cardia cancer of gastroesophageal junction. Siewert type can provide useful information for determining the appropriate surgery.
Related Articles | Metrics
Observation of GEMOX regimen combined with endostar as the first-line treatment for patients with advanced biliary tract carcinoma
LI Rong, QIN Shukui,LIU Xiufeng,GONG Xinlei,HUA Haiqing,WANG Lin,CHEN Yingxia.
Chinese Clinical Oncology. 2014, 19 (5):  430. 
Abstract ( 1027 )   PDF(pc) (1007KB) ( 499 )   Save
Objective To observe the efficacy and safety of endostar combined with gemcitabine and oxaliplatin as the firstline treatment for patients with advanced biliary tract carcinoma. Methods Forty-eight patients from Jan. 2009 to Aug. 2013 confirmed with pathologic and imaging examination as stage ⅣB primary biliary tract carcinoma were reviewed. Twenty cases received endostar+GEMOX regimen and 28 cases were applied with GEMOX regimen alone. GEMOX regimen was given as follow: gemcitabine 1000mg/m2 iv, d1,d8; oxaliplatin 100mg/m2 iv, d2, 21 days was a cycle. Endostar was given 15mg iv d1-d14, 21 days was a cycle. The efficacy was evaluated strictly after 2 cycles according to RECIST 1.1 criteria, quality of life(QoL)was evaluated accoding to karnofsky scores,safety was evaluated after 1 cycle according to NCI CTC 3.0 version criteria. The time to progress(TTP)and overall survival(OS) were also observed. Results In GEMOX+endostar group, 1 was in CR,3 in PR,12 in SD, and 4 in PD; the response rate(RR)was 20.0%, disease control rate(DCR)was 80.0%; median TTP was 8.6 months and the median OS was 14.0 months; the QoL improved and stable rate was 80.0%. In GEMOX group, 1 was in CR,5 in PR,15 in SD, and 7 in PD; RR was 21.5%, and DCR was 75.0%; the median TTP was 6.0 months and the median OS was 10.0 months; the QoL improved and stable rate was 71.4%. There was statistical difference in TTP and OS between the two groups(P<0.05). The most common toxicity in the two groups were myelosuppression, other main toxicities included nause/vommiting, liver dysfaction, peripheral nearitis, skin allergy reaction and etc, mainly in grade 1-2, and there were no sugnificant differences between the two groups(P>0.05). In GEMOX+endostar group, only 2 case of non-specific T wave changed. One case was of auricular flutter, and 1 case with mild hypertension. Conclusion GEMOX+endostar as the first-line treatment for advanced BTCs has good efficacy, may improve or stabilize the patients QoL and prolong survival, and the toxicities are well-tolerated, which worth clinical use and further observation.
Related Articles | Metrics
Effect analysis of olanzapine in cancerrelated depression and anxiety
ZHAI Xiju, LI Ruiqing.
Chinese Clinical Oncology. 2014, 19 (5):  435. 
Abstract ( 886 )   PDF(pc) (941KB) ( 463 )   Save
Objective To explore the effect of olanzapine in cancerrelated depression and anxiety and the adverse reaction.Methods One hundred and seventy-nine patients with cancer-related depression and anxiety from April 2013 to July 2013 were randomly assigned into control group(n=89) and observation group(n=90). The control group was given psychological support therapy including encouragement, help, compassion and empathy. While only the observation group received olanzapine: 5mg/day oral during radiotherapy or chemotherapy for two weeks. The treatment completion status and toxic side effects of olanzapine during use were recorded. The Zung self-rating depression scale(SDS) and selfrating anxiety scale(SAS) were employed to evaluate the status of depression and anxiety before treatment, at 2nd, 4th and 6th cycle during chemotherapy or after radiotherapy.Results The completion rates of chemotherapy at 4th and 6th cycle were higher in observation group versus control group(P>0.05). The SAS scores at 2nd, 4th and 6th cycle and SDS scores at 4th and 6th cycle during chemotherapy of observation group were lower than those of control group(P<0.05). The toxicity of olanzapine includes sleepiness, weight gain, dizziness, fatigue, dry mouth, constipation and peripheral edema. Conclusion Olanzapine can improve cancer-related anxiety and depression with the well-tolerated adverse effects.
Related Articles | Metrics
Microneurosurgery associated with gamma knife in venous sinuses meningiomas therapy
HE Yanyang, LI En, ZHOU Wutao, CUI Bingzhou.
Chinese Clinical Oncology. 2014, 19 (5):  439. 
Abstract ( 962 )   PDF(pc) (1570KB) ( 409 )   Save
Objective To investigate the efficacy and safety of microneurosurgery associated with gamma knife on venous sinuses meningiomas.
MethodsFrom June 2008 to July 2013, 34 patients with venous sinus meningiomas were underwent microneurosurgery. All the patients accepted MRI examination in 1-3 months after operation. Cases of Simpson Ⅱand Ⅲ grade resection received gamma knife therapy to decrease recurrence.Results Among the 34 patients, Simpson I, Ⅱand Ⅲ grade resection was achieved in 9, 20 and 5. Nine cases suffered muscle weakness, and no brain swelling, serious disablity and death occurred. Twenty-five cases of Simpson Ⅱand Ⅲ grade received gamma knife treatment in 1-3 month after operation with total dose of 8.20Gy. The follow-up ranged 3-36 months. One case of Simpson Ⅱ resection and 2 cases of Simpson Ⅲ resection recurred. Conclusion Patinent microsurgical treatment associated with gamma knife in the treatment of venous sinuses meningiomas shows ideal efficacy and low recurrence.
Related Articles | Metrics
临床应用
Clinical observation of paclitaxel chemotherapy by low-dose dexamethasone premedication
MA Shoudong, HU Wanning, SUN Guogui, LI Haili.
Chinese Clinical Oncology. 2014, 19 (5):  443. 
Abstract ( 1012 )   PDF(pc) (932KB) ( 461 )   Save
Objective To observe the safety and adverse reactions of the low-dose dexamethasone premedication with paclitaxel chemotherapy, explore a new paclitaxel premedication procedure. Methods Paclitaxel(135-175mg/m2) combined with platinum drugs was used in 151 patients, 21 days was a cycle. Two kinds of the premedication procedure be used before injection of paclitaxel, one in standard premedication procedure, the other in low-dose dexamethasone premedication procedure, observe the drug safety and adverse reactions. Results Paclitaxel chemotherapy in 75 cases of low-dose dexamethasone premedication and 76 cases of standards with acute allergy rates were 8.0% and 9.2%; peripheral neuritis rate were 38.7% and 40.8%, muscle and joint pain rate were 52.0%, 53.9%. There was no statistically significant between the two groups. Conclusion There was no difference in acute allergic reaction of paclitaxel chemotherapy before the application of Low-dose dexamethasone premedication compared with standards.
Related Articles | Metrics
Composite reconstruction plus hip arthroplasty in the treatment of periacetabular tumor
LU Meng, WU Sujia, SHI Xin, ZHOU Guangxin, LI Chengjun, ZHAO Jianning.
Chinese Clinical Oncology. 2014, 19 (5):  446. 
Abstract ( 982 )   Save
Objective To investigate the clinical effects of hip arthroplasty plus composite reconstruction for periacetabular tumors. Methods The hip joint was reconstructed with total artificial hip, reconstruction plate, screws, wire and bone cement. The patients were followed up postoperatively. The functional assessment was conducted with the Musculoskeletal Tumor Society Rating Scale(MSTS). Results Despite of 1 patient with sudden death due to bilateral pulmonary embolism, the rest were successfully operated. Twenty-three patients could basically walk properly with 11 cases of normal hip function and 10 cases of hip flexion function partially restored. There were 5 patients of delayed wound healing. Out of 2 patients with peroneal nerve injure, one got recovery at 6th month postoperative and one did not restore during the followup with the use of protective brace. The followup ranged 12 to 84 months with the median of 40.0 month and the follow-up rate reached 1000%. Two patients died and four recurred(2 patients died), while 21 patients survived(13 cases of tumorfree survival, 8 cases survived with tumor). The MSTS score was(23.8±9.2) with excellent rate of 87.0%(20/23).Conclusion The hip function was good in patients with periacetabular tumors after hip arthroplasty plus composite reconstruction during short-time follow-up.
Related Articles | Metrics
Clinical application of ultrasound-guided percutaneous lung biopsy in peripheral pulmonary masses
YANG Zhiying,ZHENG Hao, ZHANG Qi, LIU Lei, ZHOU Weili.
Chinese Clinical Oncology. 2014, 19 (5):  449. 
Abstract ( 944 )   Save
Objective To study the clinical value and complications of ultrasoundguided lung biopsy in diagnosis of peripheral pulmonary masses. Methods One hundred and seventy-three cases with peripheral pulmonary masses were enrolled and directly applied percutaneous lung biopsy using needle aspiration under ultrasound guiding after examining. Biopsy samples were performed by cytology and histopathological examination. Results Successful procedures were performed in all cases. Masses were found by both cytological and histological examination with diagnostic accuracy rate of 96.0%(166/173). Biopsyrelated complications occurred in 22 patients, including blooding in 9 patients(5.2%)and pneumothorax in 13(7.5%). Conclusion Ultrasound-guided percutaneous peripheral pulmonary lesions biopsy is a safe and effective tool in the diagnosis and management of peripheral pulmonary disease.
Related Articles | Metrics
指南与解读
Expert consensus on antiviral therapy to hepatitis B/C virusrelated hepatocellular carcinoma

Expert panel of antiviral therapy for hepatocellular carcinoma

Chinese Clinical Oncology. 2014, 19 (5):  452. 
Abstract ( 725 )   PDF(pc) (951KB) ( 385 )   Save
Related Articles | Metrics
综述与讲座
Circumventing drug resistance of tumor cells by induction of necroptosis
DENG Xiuwen, ZOU Wen.
Chinese Clinical Oncology. 2014, 19 (5):  460. 
Abstract ( 1002 )   PDF(pc) (992KB) ( 411 )   Save
Necroptosis is a caspase-independent, regulable programmed cell death pathway, which possesses the same morphological characteristics of necrosis and similar molecular biological characteristics with apoptosis. Currently, the main obstacle in chemotherapy is drug resistance of tumor cells, mainly due to multidrug resistance mediated by high expression of ATP-dependent drug transporters and the blockade of apoptosis pathway. Thus, the induction of necroptosis may act as a potentially powerful weapon to reverse a variety of tumor resistance. This review includes three parts: necroptosis, its relation with apoptosis and autophagy, drug resistance mechanism of tumor cells and recent advances in the induction of necroptosis.
Related Articles | Metrics
Progress in the treatment of gastrointestinal stromal tumor
ZHAO Chuanhua,XU Jianming.
Chinese Clinical Oncology. 2014, 19 (5):  465. 
Abstract ( 992 )   Save
As the most common mesenchymal tumor of gastrointestinal tract,gastrointestinal stromal tumor(GIST) has been paid more and more attention. In the recent 10 years,with studies on molecular mechanism of GIST,and emergence of molecular targeted drugs represented by imatinib mesylate,traditional treatment concepts of GIST have been updated. Surgical resection combined with molecular targeted drugs is becoming the treatment mode for GIST. Molecular targeted therapy has significantly improved the prognosis and prolong the survival of GIST patients. However, for different stages of GIST,many questions on how to apply the targeted drugs reasonably still remain to be answered. This article summarizes the latest progress on the perioperative treatment of GIST and systemic therapy for advanced GIST.
Related Articles | Metrics
The research progress of hPTTG1 in the occurrence and development of tumors
GAO Yingjie,YANG Juan,ZHANG Chao,HAN Jingchun.
Chinese Clinical Oncology. 2014, 19 (5):  469. 
Abstract ( 961 )   Save
As a potential oncogene, human pituitary tumor transforming gene(hPTTG) has been always the research foucs since it was discovered. hPTTG1 is mainly expressed in human tumors and highly expressed in a variety of tumors. Related studies have shown that hPTTG1 has the function of promoting cell transformation, angiogenesis, tumor metastasis and other biological functions. Besides, it plays an important role in tumorigenesis,occurrence,development,invasion, metastasis and recurrence of tumors. hPTTG1 has important reference value for diagnosis of tumor, and it represents potential target for gene therapy of tumor.
Related Articles | Metrics
Progress of miR-155 and digestive system neoplasms
JIANG Wenyang, KANG Ganjun, XIE Songping, HUANG Jie.
Chinese Clinical Oncology. 2014, 19 (5):  473. 
Abstract ( 964 )   Save
MicroRNA(miRNA) is a group of tiny RNA molecules which wildly exists in nature world. It was once considered as meaningless fragments generated during RNA maturation. However, in recent years, miRNA was found to be pivotal molecules in a variety of physiological and pathological processes in human beings. As a representative member of miRNA, miR-155 played important regulatory roles in the occurrence and progression of a large number of tumors. In this article, progress in the relationship between miR-155 and digestive system neoplasms was reviewed.
Related Articles | Metrics